NCT05090111

A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia

A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia, and an Open-Label Assessment of Bioavailability and Food-effect in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 98 (actual)
• Sponsor: Aligos Therapeutics · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

A Randomized Study of ALG-055009 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses in Healthy Volunteers and Subjects with Hyperlipidemia

Conditions

• NASH - Nonalcoholic Steatohepatitis

Interventions

Type	Name	Description
DRUG	ALG-055009	Single or multiple doses of ALG-055009
DRUG	Placebo	Single or multiple doses of Placebo

Timeline

• Start date: 2021-12-01
• Primary completion: 2023-06-16
• Completion: 2023-06-16
• First posted: 2021-10-22
• Last updated: 2023-09-25

Locations

1 site across 1 country: France